Literature DB >> 29695586

GREB1 isoforms regulate proliferation independent of ERα co-regulator activities in breast cancer.

Corinne N Haines1,2, Kara M Braunreiter1, Xiaokui Molly Mo3, Craig J Burd4,2.   

Abstract

Activation of the transcription factor estrogen receptor α (ERα) and the subsequent regulation of estrogen-responsive genes play a crucial role in the development and progression of the majority of breast cancers. One gene target of ERα, growth regulation by estrogen in breast cancer 1 (GREB1), is associated with proliferation and regulation of ERα activity in estrogen-responsive breast cancer cells. The GREB1 gene encodes three distinct isoforms: GREB1a, GREB1b and GREB1c, whose molecular functions are largely unknown. Here, we investigate the role of these isoforms in regulation of ERα activity and proliferation. Interaction between GREB1 and ERα was mapped to the amino terminus shared by all GREB1 variants. Analysis of isoform-specific regulation of ERα activity suggests none of the GREB1 isoforms possess potent co-regulator activity. Exogenous expression of GREB1a resulted in elevated expression of some ER-target genes, independent of ERα activity. Despite this slight specificity of GREB1a for gene regulation, exogenous expression of either GREB1a or GREB1b resulted in decreased proliferation in both ER-positive and ER-negative breast carcinoma cell lines, demonstrating an ER-independent function of GREB1. Interestingly, we show an increase in the expression of GREB1b and GREB1c mRNA in malignant breast tissue compared to normal patient samples, suggesting a selective preference for these isoforms during malignant transformation. Together, these data suggest GREB1a has an isoform-specific function as a transcriptional regulator while all isoforms share an ER-independent activity that regulates proliferation.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  breast cancer; estrogen receptor; gene expression; proliferation

Mesh:

Substances:

Year:  2018        PMID: 29695586      PMCID: PMC7158201          DOI: 10.1530/ERC-17-0496

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  20 in total

1.  Sustained reprogramming of the estrogen response after chronic exposure to endocrine disruptors.

Authors:  Andrea R Patterson; Xiaokui Mo; Ali Shapiro; Karen E Wernke; Trevor K Archer; Craig J Burd
Journal:  Mol Endocrinol       Date:  2015-01-16

2.  Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.

Authors:  Dirk O Bauerschlag; Ole Ammerpohl; Karen Bräutigam; Christian Schem; Qiong Lin; Marion T Weigel; Felix Hilpert; Norbert Arnold; Nicolai Maass; Ivo Meinhold-Heerlein; Wolfgang Wagner
Journal:  Oncology       Date:  2011-05-16       Impact factor: 2.935

3.  Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced pS2 expression.

Authors:  T R Zacharewski; K L Bondy; P McDonell; Z F Wu
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

4.  Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody.

Authors:  H J Hnatyszyn; M Liu; A Hilger; L Herbert; C R Gomez-Fernandez; M Jorda; D Thomas; J M Rae; D El-Ashry; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  2009-10-20       Impact factor: 4.872

5.  Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells.

Authors:  Jun Sun; Zafar Nawaz; Joyce M Slingerland
Journal:  Mol Endocrinol       Date:  2007-07-31

6.  Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences.

Authors:  Julie Deschênes; Véronique Bourdeau; John H White; Sylvie Mader
Journal:  J Biol Chem       Date:  2007-04-26       Impact factor: 5.157

Review 7.  Endocrine-responsive breast cancer and strategies for combating resistance.

Authors:  Simak Ali; R Charles Coombes
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

8.  Recurrent read-through fusion transcripts in breast cancer.

Authors:  Katherine E Varley; Jason Gertz; Brian S Roberts; Nicholas S Davis; Kevin M Bowling; Marie K Kirby; Amy S Nesmith; Patsy G Oliver; William E Grizzle; Andres Forero; Donald J Buchsbaum; Albert F LoBuglio; Richard M Myers
Journal:  Breast Cancer Res Treat       Date:  2014-06-15       Impact factor: 4.872

9.  Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells.

Authors:  Jian-Rong Li; Chuan-Hu Sun; Wenyuan Li; Rou-Fang Chao; Chieh-Chen Huang; Xianghong Jasmine Zhou; Chun-Chi Liu
Journal:  Nucleic Acids Res       Date:  2015-11-23       Impact factor: 19.160

10.  17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo.

Authors:  Laura A Laviolette; Kendra M Hodgkinson; Neha Minhas; Carol Perez-Iratxeta; Barbara C Vanderhyden
Journal:  Int J Cancer       Date:  2014-02-25       Impact factor: 7.396

View more
  9 in total

1.  GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation.

Authors:  Corinne N Haines; Hope D Klingensmith; Makanko Komara; Craig J Burd
Journal:  Carcinogenesis       Date:  2020-12-31       Impact factor: 4.944

Review 2.  Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers.

Authors:  Meng Cheng; Stephanie Michalski; Ramakrishna Kommagani
Journal:  Int J Mol Sci       Date:  2018-08-28       Impact factor: 5.923

3.  The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.

Authors:  Maria F Ogara; Santiago A Rodríguez-Seguí; Melisa Marini; Ana Silvina Nacht; Martin Stortz; Valeria Levi; Diego M Presman; Guillermo P Vicent; Adali Pecci
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

4.  GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ERα glycosylation and stability to cancer.

Authors:  Eun Myoung Shin; Vinh Thang Huynh; Sultan Abda Neja; Chia Yi Liu; Anandhkumar Raju; Kelly Tan; Nguan Soon Tan; Jayantha Gunaratne; Xuezhi Bi; Lakshminarayan M Iyer; L Aravind; Vinay Tergaonkar
Journal:  Sci Adv       Date:  2021-03-17       Impact factor: 14.136

5.  Impact of 6 month conjugated equine estrogen versus estradiol-treatment on biomarkers and enriched gene sets in healthy mammary tissue of non-human primates.

Authors:  Gabriel Hobi; J Mark Cline; Kelly F Ethun; Cedric Simillion; Irene Keller; Petra Stute
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

6.  Combined Estrogen Alpha and Beta Receptor Expression Has a Prognostic Significance for Colorectal Cancer Patients.

Authors:  Geriolda Topi; Souvik Ghatak; Shakti Ranjan Satapathy; Roy Ehrnström; Marie-Louise Lydrup; Anita Sjölander
Journal:  Front Med (Lausanne)       Date:  2022-03-14

7.  PRMT1, a Key Modulator of Unliganded Progesterone Receptor Signaling in Breast Cancer.

Authors:  Lucie Malbeteau; Julien Jacquemetton; Cécile Languilaire; Laura Corbo; Muriel Le Romancer; Coralie Poulard
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

8.  Comprehensive Analysis of GDF10 Methylation Site-Associated Genes as Prognostic Markers for Endometrial Cancer.

Authors:  Jingyi Fan; Huaijun Zhou
Journal:  J Oncol       Date:  2022-10-10       Impact factor: 4.501

9.  Nursing Genetic Research: New Insights Linking Breast Cancer Genetics and Bone Density.

Authors:  Antonio Sanchez-Fernandez; Raúl Roncero-Martin; Jose M Moran; Jesus Lavado-García; Luis Manuel Puerto-Parejo; Fidel Lopez-Espuela; Ignacio Aliaga; María Pedrera-Canal
Journal:  Healthcare (Basel)       Date:  2020-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.